Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2a.

Combined chemo-/immunotherapy has shown high objective response rates and a significant though small proportion of long-term complete responders in metastatic malignant melanoma. The purpose of this study was to determine response rates, freedom from treatment failure (FFTF) and overall survival in...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Hoffmann, R., Müller, I., Neuber, K., Lassmann, S., Buer, J., Probst, M., Oevermann, K., Franzke, A., Kirchner, H., Ganser, A., Atzpodien, J.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group|1 1998
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2063152/
https://ncbi.nlm.nih.gov/pubmed/9792153
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi